AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$CSTL

MAETZOLD DEREK J sold $204K of CSTL (indirect holdings)

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 6,132 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $33.20 ($33.14–$33.88, $0.20M total) across 12 trades on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Sep 1, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short‑term traders monitoring insider sentiment.

02

Market read

A modest insider sale from the CEO may cause slight price pressure but is unlikely to move the broader market.

03

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 3/10Novelty 5/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

CEO Derek Maetzold sold 6,132 shares for $203,562.28 via a 10b5‑1 plan, reducing his stake to 11,256 shares.

Expected impact

Possible modest downside of 1‑2% as market digests the sale.

Evidence & confidence

The sale size is modest relative to market cap, but it comes from the CEO under a pre‑arranged plan, limiting immediate speculation.

Market effects

Sector

May prompt scrutiny of biotech insider activity but limited sector impact.

Regional

U.S. biotech market unchanged.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be routine portfolio management, not a negative signal.

Key entities

  • Officer
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences

  • Company
    Castle Biosciences Inc.

    Biotech firm developing diagnostic platforms

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min